Filing Flows › Viridian Therapeutics (VRDN) › R&D spending
Viridian Therapeutics (VRDN) R&D spending by quarter
Viridian Therapeutics' R&D spending was $70.1M in Q3 2026 (third quarter 2026), -2% from Q2 2026. Over the last 7 quarters it ranged from $70.1M (Q3 2026) to $89.2M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $70.1M | -2% | -19% |
| Q2 2026 | $71.6M | -8% | -17% |
| Q1 2026 | $77.6M | -13% | +1% |
| Q4 2025 | $89.2M | +3% | — |
| Q3 2025 | $86.3M | -0.4% | — |
| Q2 2025 | $86.6M | +13% | — |
| Q1 2025 | $76.8M | — | — |
Q3 2026 at a glance
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Viridian Therapeutics' R&D spending?
Viridian Therapeutics' R&D spending was $70.1M in Q3 2026 (third quarter 2026), -2% from Q2 2026.
How has Viridian Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $70.1M (Q3 2026) to $89.2M (Q4 2025).